Overall, sPD-1 is shown to increase anti-tumor immunity through in vitro and in vivo blockade of PD-L1 and PD-L2 present on DCs and cancer cells with an increase in activation, cytotoxicity, cytokine production, and infiltration of CD8+ T cells. This evidence concerns the gene PDCD1LG2 and neoplasm.